Original Article
Effect of Long-Term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma
N Engl J Med 2000; 343:1064-1069October 12, 2000
- Abstract
Background
Short-term studies have shown that inhaled corticosteroids may reduce the growth of children with asthma. However, the effect of long-term treatment on adult height is uncertain.
Methods
We conducted a prospective study in children with asthma to examine the effect of long-term treatment with inhaled budesonide on adult height. We report on 211 children who have attained adult height: 142 budesonide-treated children with asthma, 18 control patients with asthma who have never received inhaled corticosteroids, and 51 healthy siblings of patients in the budesonide group, who also served as controls.
Results
The children in the budesonide group attained adult height after a mean of 9.2 years of budesonide treatment (range, 3 to 13) at a mean daily dose of 412 μg (range, 110 to 877). The mean cumulative dose of budesonide was 1.35 g (range, 0.41 to 3.99). The mean differences between the measured and target adult heights were +0.3 cm (95 percent confidence interval, –0.6 to +1.2) for the budesonide-treated children, –0.2 cm (95 percent confidence interval, –2.4 to +2.1) for the control children with asthma, and +0.9 cm (95 percent confidence interval, –0.4 to +2.2) for the healthy siblings. The adult height depended significantly (P<0.001) on the child's height before budesonide treatment. Although growth rates were significantly reduced during the first years of budesonide treatment, these changes in growth rate were not significantly associated with adult height.
Conclusions
Children with asthma who have received long-term treatment with budesonide attain normal adult height.
Media in This Article
Figure 3
Differences between the Measured Adult Height and the Target Adult Height as a Function of the Duration of Budesonide Treatment (Panel A) and Cumulative Prescribed Budesonide Dose (Panel B).Figure 1
Status of the 332 Children Included in the Study as of August 1999.Article Activity
- Article
Because they are effective, inhaled corticosteroids are widely used to treat children with asthma.1-3 However, many physicians are concerned about the potential adverse effects of long-term corticosteroid treatment, particularly effects on growth.
In many trials assessing growth during therapy with inhaled corticosteroids, follow-up observations have been conducted for one year or less. Although such studies may provide useful information, their relevance to actual practice is uncertain.4 Several studies have reported poor correlations between corticosteroid-induced short-term changes in the growth rate of the lower leg and total body growth during the subsequent year.5-10 Furthermore, the correlation between consecutive annual measurements of statural height velocity in normal prepubertal children is poor, with only partial correlation between values at one, two, three, and four years.8 Height velocity computed over periods of three and four years during childhood explains only 34 percent and 38 percent, respectively, of the variation in adult height.8
Since 1986, we have been conducting a prospective study of children with persistent asthma to assess total body growth, weight gain, lung function, and hospitalization for asthma exacerbations.2,11,12 We report here the 10-year growth data for the children who have reached adult height. We also report how growth rate and changes in growth rate relate to adult height.
Methods
Study Design
Children with asthma were recruited for a prospective, long-term study.2,11,12 We excluded those with other chronic diseases or with a gestational age of less than 32 weeks. All children visited the clinic at six-month intervals for one to two years (the run-in period). During this period, asthma medication was adjusted according to the Danish pediatric-asthma guidelines in use at the time.13 Three hundred thirty-two children whose asthma was considered to be acceptably controlled without the continuous use of inhaled corticosteroids were then asked to change to treatment with the inhaled corticosteroid budesonide, because several studies had indicated that inhaled corticosteroids should be used more frequently.14,15 The proposed change in therapy was accepted by the families of 270 children (the budesonide group). The families of 62 children declined to change therapy because of concern about side effects or satisfaction with their current therapy. These children (the controls) continued to take the medication they had used during the run-in period. Control patients were able to change to inhaled budesonide if they chose to at a later time. The study was approved by the ethics committee of Vejle and Fyns counties, and oral informed consent was obtained from all families.
At each six-month visit, we recorded the number of hospital admissions for acute asthma, age, height (mean of three measurements with a Harpenden stadiometer), weight, lung function (as assessed with a bellows spirometer), the dose and frequency of administration of all prescribed drugs, the dose of inhaled budesonide, and the inhalation device used. Changes in medication, if any, were based on a combination of history, lung function, use of a β2-agonist for rescue therapy, and diary recordings. During the first six years of the study, fixed clinical criteria were used to initiate changes in medication.2 After this time, the criteria were more flexible.
Throughout the study, the patients were seen by the same two physicians, and all measurements of weight, height (including the heights of siblings and parents), and lung function were performed by the same three nurses. Between scheduled visits, all changes in asthma medication were made under the supervision of the clinic personnel and were recorded. Any asthma medication required to control the disease was allowed. Data for children who received prednisolone for more than an average of two weeks per year were excluded from the analysis of adult height. Compliance with asthma medication was checked at each visit by direct questioning and by recording the frequency of renewal of prescriptions.
The data analyzed here were collected from January 1986 through August 1999. The status of the 332 originally enrolled patients at the end of this period is shown in Figure 1Figure 1
Status of the 332 Children Included in the Study as of August 1999.. Among those who had reached adult height and for whom information on parental height was available, there remained 142 subjects in the budesonide group and 18 in the control group. The mean age at the diagnosis of asthma was 3.4 years (range, 1 to 10) in the budesonide group and 4.3 years (range, 1 to 9) in the control group. Because data on adult height in children who were not using inhaled corticosteroids were limited because of the small number of children remaining in the control group, the healthy siblings of the children in the budesonide group were recruited for measurement of adult height. There were 149 siblings, of whom 105 had reached adult height. Of these, 38 had received treatment with inhaled corticosteroids and 16 refused to participate, leaving 51 healthy siblings for analysis (Table 1Table 1
Characteristics of the Study Subjects.).Statistical Analysis
Data were transformed into standard-deviation scores as described by Tanner et al.,16 according to the following formula: (measured height – mean height for age) ÷ standard deviation of height for age. The measured adult height was the height measured when the height of a child over 15 years of age had increased by less than 0.5 cm for two consecutive years.
The target adult height was calculated as described by Luo et al.,17,18 with the addition of 0.7 cm to the height for boys and 1.0 cm to the height for girls because of trends over time, as 45.99 + 0.78x + 0.7 cm for boys and 37.85 + 0.75x + 1.0 cm for girls, where x is the father's height and the mother's height summed and divided by 2.
The primary outcome was the measured adult height in relation to the target adult height. The difference between the measured and the target height was analyzed by the paired-samples t-test. The assumption of normality was examined by probability plot and accepted.19
We assessed the following secondary outcomes: whether the difference between the measured height and the target adult height depended on the mean daily budesonide dose, the total cumulative budesonide dose, the duration of treatment, the duration of asthma at the beginning of treatment or at the time of attainment of adult height, the use or nonuse of intranasal corticosteroids, the growth rate, the standard-deviation score for height or the forced expiratory volume in one second (FEV1) before budesonide treatment, and the growth rate and the changes in the growth rate or standard-deviation score for height during the first year of budesonide treatment. The tests were performed by analysis of variance and covariance. All tests were performed for the whole group of children and for girls and boys separately. All reported P values are two-tailed.19
Results
The budesonide-treated children reached their target adult height (Figure 2Figure 2
Measured Adult Height in Relation to Target Adult Height in 142 Children Treated with Inhaled Budesonide for 3 to 13 Years.) to the same extent as their healthy siblings and the children in the control group (Table 2Table 2
Measured and Target Adult Heights.). There was no reason to suspect that the 20 children who were older than 14 years of age and who had not yet reached their adult height would attain an adult height markedly less than their target adult height. In all groups, more than 95 percent of the children attained an adult height that was within 9 cm above or below their target adult height.The mean cumulative dose of budesonide at the time of attainment of adult height was 1.35 g (range, 0.41 to 3.99). The mean duration of budesonide treatment at this time was 9.2 years (range, 3 to 13), yielding a mean average daily budesonide dose of 412 μg (range, 110 to 877). Twenty children in the budesonide group who were more than 15 years old had not yet reached their adult height. Their mean cumulative dose of budesonide (1.25 g; range, 0.40 to 3.12) was not significantly different from that of the children who had attained their adult height (P=0.72). There was no significant correlation between the duration of treatment (P=0.16) or the cumulative dose of budesonide (P=0.14) and the difference between the measured and target adult heights (Figure 3Figure 3
Differences between the Measured Adult Height and the Target Adult Height as a Function of the Duration of Budesonide Treatment (Panel A) and Cumulative Prescribed Budesonide Dose (Panel B).).The difference between the measured and target adult heights was not significantly associated with the subject's sex (P=0.30), age at the beginning of budesonide treatment (P=0.13), age at which adult height was attained (P=0.82), or duration of asthma before the start of budesonide treatment (P=0.37).
The standard-deviation score for height and the FEV1 as a percentage of the predicted value before the start of budesonide treatment were correlated (P= 0.05), indicating that the severity of asthma influenced growth. Budesonide treatment was associated with a significant change in the growth rate during the first years of treatment, as compared with the run-in period. The mean growth rate was 6.1 cm per year (95 percent confidence interval, 5.7 to 6.5) during the run-in period, 5.1 cm per year (95 percent confidence interval, 4.7 to 5.5; P<0.001) during the first year of treatment, 5.5 cm per year (95 percent confidence interval, 5.1 to 5.9; P=0.02) during the second year, and 5.9 cm per year (95 percent confidence interval, 5.5 to 6.3; P=0.53) during the third year. However, the changes in growth rate during this period were not correlated with the differences between the measured and target adult heights (P= 0.44). The initial growth retardation was significantly correlated with age (P=0.04), with a more pronounced reduction in younger children.
The standard-deviation score for height before budesonide treatment and the difference between the measured and target adult heights were correlated (P<0.001), so that children with a low standard-deviation score for height before treatment had a smaller adult height than expected. There was a trend toward an association between the difference between the measured and target adult heights and the duration of asthma at the time adult height was measured (P=0.07).
Forty children in the budesonide group used intranasal corticosteroids for an average of 24 months (range, 6 to 72). The adult height of these children was similar to that of the children who had never used intranasal corticosteroids (P=0.99). Moreover, the difference between the measured and target adult heights was not associated with the cumulative number of months of use of intranasal corticosteroids (P=0.72).
Compliance with budesonide treatment was calculated according to the following formula: 100 × (number of doses taken ÷ number of doses prescribed). The mean estimated compliance was 68 percent (range, 49 to 90 percent). The difference between the measured and target adult heights was not associated with compliance (P=0.38).
Discussion
We found that children with asthma who had received long-term treatment with inhaled budesonide attained normal adult height. Furthermore, we found no evidence of a dose–response relation between the mean daily dose of budesonide, the cumulative dose of budesonide, or the duration of budesonide treatment and the difference between the measured and target adult heights. Our findings suggest that long-term treatment with inhaled budesonide does not have any clinically important adverse effects on adult height. This corroborates the results of retrospective studies of smaller groups of children treated for shorter periods with inhaled corticosteroids20,21 and a prospective study of 66 children who were followed for 13 years until they reached adult height.22
Normally, 95 percent of the population is expected to attain an adult height within 9 cm above or below their target adult height.18 This was true for the patients in our study, indicating that great individual sensitivity to the systemic effects of inhaled budesonide was uncommon.
Several studies of growth during a period of one year have reported growth retardation of approximately 1.5 cm per year in children treated with 400 μg of inhaled beclomethasone per day, as compared with those receiving placebo.23-26 These data have led to the inclusion of warnings about growth retardation in the package inserts for inhaled corticosteroids in the United States. Our results show the effects of continuous treatment for 10 years at the same mean corticosteroid dose as in the 1-year studies. The growth rate during the first year of treatment was on average 1 cm less than that during the run-in period. Thus, our results are consistent with those of shorter studies of beclomethasone. The initial reduction in the annual growth rate did not persist, however, and the adult height was not adversely affected. Furthermore, the initial growth retardation in individual children had no relation to differences between the measured and target adult heights. The reason for the absence of a relation is not clear. Others have also found the growth-retarding effect of inhaled corticosteroids to be more marked during the beginning of treatment.26-28 Differences in compliance over time did not seem to be the cause.
Another reason for the discrepancy between short-term studies and studies of adult height could be that pubertal children are less sensitive than prepubertal children to the growth-retarding effect of exogenous corticosteroids, as we and others25 have found. Most growth studies have been performed in children six through nine years of age. Finally, exogenous corticosteroids may retard bone maturation to the same extent that they retard growth.29-32 This possibility is difficult to assess in children with chronic asthma, regardless of whether they use inhaled corticosteroids. Such children often have retarded bone maturation, prepubertal growth retardation, and a delayed onset of puberty.22,33-35
A weakness of our study is that there were few children remaining in the control group by the time they reached adult height. Therefore, we measured the adult heights of healthy siblings of budesonide-treated children, whose genetic growth potential and living conditions were very similar to those of the subjects in the study group. Although a randomized, double-blind design would have been ideal, this was not possible in our 15-year study. The demographic similarities among the various groups suggest that they were reasonably comparable.
Generally, asthma in our patients was well controlled once treatment with inhaled budesonide was initiated. This made it difficult to assess how the severity of asthma influenced growth. The correlation between the FEV1 as a percentage of the predicted value and the standard-deviation score for height before budesonide treatment suggests that severe asthma may in itself have a negative effect on growth, as observed in other studies.36,37 It is less clear whether severe asthma also has an adverse effect on adult height. The strong correlation between the standard-deviation score for height before treatment and the adult height suggests that severe asthma may also adversely affect adult height. This is in agreement with findings in other studies.20,34,35 However, many patients in the control group who had more severe disease dropped out of our study. Thus, among those who stayed in the study long enough to have their adult height measured, either the disease was milder or the asthma had gone into remission.
Supported by grants from the Vejle County Hospitals Research Fund.
Source Information
From the Department of Pediatrics, University of Southern Denmark and Kolding Hospital, Kolding, Denmark.
Address reprint requests to Dr. Agertoft at the Department of Pediatrics, Kolding Hospital, DK-6000 Kolding, Denmark, or at lone_agertoft@dadlnet.dk.
- References
References
1
Barnes PJ ,Pedersen S ,Busse WW . Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:S1-S53
Web of Science | Medline2
Agertoft L ,Pedersen S . Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-381
CrossRef | Web of Science | Medline3
Barnes PJ ,Pedersen S . Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993;148:S1-S126
Web of Science | Medline4
Allen DB . Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids. Allergy 1999;54:Suppl 29:29-34
CrossRef | Web of Science | Medline5
Marshall W . Evaluation of growth rate in height over periods of less than one year. Arch Dis Child 1971;46:414-420
CrossRef | Web of Science | Medline6
Butler GE ,McKie M ,Ratcliffe SG . The cyclical nature of prepubertal growth. Ann Hum Biol 1990;17:177-198
CrossRef | Web of Science | Medline7
Voss LD ,Wilkin TJ ,Bailey BJR ,Betts PR . The reliability of height and height velocity in the assessment of growth. Arch Dis Child 1991;66:833-837
CrossRef | Web of Science | Medline8
Karlberg J ,Gelander L ,Albertsson-Wikland K . Distinctions between short- and long-term human growth studies. Acta Paediatr 1993;82:631-634
CrossRef | Web of Science | Medline9
Karlberg J ,Low L ,Yeung CY . On the dynamics of the growth process. Acta Paediatr 1994;83:777-778
CrossRef | Web of Science | Medline10
Gelander L ,Karlberg J ,Albertsson-Wikland K . Seasonality in lower leg length velocity in prepubertal children. Acta Paediatr 1994;83:1249-1254
CrossRef | Web of Science | Medline11
Agertoft L ,Pedersen S . Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med 1998;157:178-183
Web of Science | Medline12
Agertoft L ,Larsen FE ,Pedersen S . Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998;12:130-135
CrossRef | Web of Science | Medline13
Warner JO ,Gotz M ,Landau LI , et al. Management of asthma: a consensus statement. Arch Dis Child 1989;64:1065-1079
CrossRef | Web of Science | Medline14
Clissold SP ,Heel RC . Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518
CrossRef | Web of Science | Medline15
Henriksen JM . Effect of inhalation of corticosteroids on exercise induced asthma: randomised double blind crossover study of budesonide in asthmatic children. BMJ 1985;291:248-249
CrossRef | Web of Science | Medline16
Tanner JM ,Whitehouse RH ,Takaishi M . Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch Dis Child 1966;41:454-471
CrossRef | Web of Science | Medline17
Luo ZC ,Low LC ,Karlberg J . A comparison of target height estimated and final height attained between Swedish and Hong Kong Chinese children. Acta Paediatr 1999;88:248-252
CrossRef | Web of Science | Medline18
Luo ZC ,Albertsson-Wikland K ,Karlberg J . Target height as predicted by parental heights in a population-based study. Pediatr Res 1998;44:563-571
CrossRef | Web of Science | Medline19
Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley, 1986.
20
Van Bever HP ,Desager KN ,Lijssens N ,Weyler JJ ,Du Caju MV . Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol 1999;27:369-375
CrossRef | Web of Science | Medline21
Silverstein MD ,Yunginger JW ,Reed CE , et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997;99:466-474
CrossRef | Web of Science | Medline22
Balfour-Lynn L . Growth and childhood asthma. Arch Dis Child 1986;61:1049-1055
CrossRef | Web of Science | Medline23
Doull IJ ,Freezer NJ ,Holgate ST . Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715-1719
Web of Science | Medline24
Tinkelman DG ,Reed CE ,Nelson HS ,Offord KP . Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77
Web of Science | Medline25
Verberne AAPH ,Frost C ,Roorda RJ ,van der Laag H ,Kerrebijn KF . One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-695
Web of Science | Medline26
Simons FER, Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group
Full Text | Web of Science | Medline27
Saha MT ,Laippala P ,Lenko HL . Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids. Acta Paediatr 1997;86:138-142
CrossRef | Web of Science | Medline28
Doull IJ ,Campbell MJ ,Holgate ST . Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1998;78:172-173
CrossRef | Web of Science | Medline29
Aicardi G ,Benso L ,Vignolo M , et al. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. Br J Rheumatol 1993;32:Suppl 2:39-43
Medline30
Vignolo M ,Milani S ,Imbimbo B , et al. Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (deflazacort) versus prednisone: an interim study. Clin Exp Rheumatol 1991;9:Suppl 6:41-45
Web of Science | Medline31
Oberger E ,Taranger J ,Bruning B ,Engstrom I ,Karlberg J . Long-term treatment with corticosteroids/ACTH in asthmatic children. IV. Skeletal maturation. Acta Paediatr Scand 1986;75:744-749
CrossRef | Web of Science | Medline32
Morris HG . Growth and skeletal maturation in asthmatic children: effect of corticosteroid treatment. Pediatr Res 1975;9:579-583
CrossRef | Web of Science | Medline33
Ferguson AC ,Murray AB ,Tze WJ . Short stature and delayed skeletal maturation in children with allergic disease. J Allergy Clin Immunol 1982;69:461-466
CrossRef | Web of Science | Medline34
Hauspie R ,Susanne C ,Alexander F . Maturational delay and temporal growth retardation in asthmatic boys. J Allergy Clin Immunol 1977;59:200-206
CrossRef | Web of Science | Medline35
Martin AJ ,Landau LI ,Phelan PD . The effect on growth of childhood asthma. Acta Pediatr Scand 1981;70:683-688
CrossRef | Web of Science | Medline36
Ninan T ,Russell G . Asthma, inhaled corticosteroid treatment, and growth. Arch Dis Child 1992;67:703-705
CrossRef | Web of Science | Medline37
McCowan C ,Neville RG ,Thomas GE , et al. Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. BMJ 1998;316:668-672
CrossRef | Web of Science | Medline
- Citing Articles (174)
Citing Articles
1
S. R. Nimmagadda. (2012) Growth of Preschool Children After Discontinuation of Fluticasone. AAP Grand Rounds 27:2, 16-16
CrossRef2
C. Lee, W.B. Klaustermeyer. (2012) Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma. Allergologia et Immunopathologia
CrossRef3
Pakit Vichyanond, Rattana Pensrichon, Suruthai Kurasirikul. (2012) Progress in the management of childhood asthma. Asia Pacific Allergy 2:1, 15
CrossRef4
Paul L.P. Brand. (2011) Inhaled corticosteroids should be the first line of treatment for children with asthma. Paediatric Respiratory Reviews 12:4, 245-249
CrossRef5
Paolo Montuschi, Peter J. Barnes. (2011) New perspectives in pharmacological treatment of mild persistent asthma. Drug Discovery Today 16:23-24, 1084-1091
CrossRef6
Theresa W. Guilbert, David T. Mauger, David B. Allen, Robert S. Zeiger, Robert F. Lemanske, Stanley J. Szefler, Robert C. Strunk, Leonard B. Bacharier, Ronina Covar, Christine A. Sorkness, Lynn M. Taussig, Fernando D. Martinez. (2011) Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. Journal of Allergy and Clinical Immunology 128:5, 956-963.e7
CrossRef7
David P. Skoner, Eli O. Meltzer, Henry Milgrom, Paul Stryszak, Ariel Teper, Heribert Staudinger. (2011) Effects of Inhaled Mometasone Furoate on Growth Velocity and Adrenal Function: A Placebo-Controlled Trial in Children 4–9 Years Old with Mild Persistent Asthma. Journal of Asthma 48:8, 848-859
CrossRef8
Iva M. Stefanovic, Eva Verona, Biserka Cicak, Renata Vrsalovic. (2011) No effect of fluticasone propionate on linear growth in preschool children with asthma. Pediatrics International 53:5, 672-676
CrossRef9
George W. Bensch, Leon S. Greos, Sandra Gawchik, Euloge Kpamegan, Kenneth B. Newman. (2011) Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double-blind, placebo-controlled trial. Annals of Allergy, Asthma & Immunology 107:4, 323-329
CrossRef10
Wim M. C. Aalderen, Aline B. Sprikkelman. (2011) Inhaled corticosteroids in childhood asthma: the story continues. European Journal of Pediatrics 170:6, 709-718
CrossRef11
Paul LP Brand. (2011) Treatment of mild persistent asthma in children. The Lancet 377:9779, 1743
CrossRef12
Sophie Flammarion, Clarisse Santos, Dominique Guimber, Lyne Jouannic, Caroline Thumerelle, Frédéric Gottrand, Antoine Deschildre. (2011) Diet and nutritional status of children with food allergies. Pediatric Allergy and Immunology 22:2, 161-165
CrossRef13
Mark Anselmo. (2011) Pediatric Asthma Controller Therapy. Pediatric Drugs 13:1, 11-17
CrossRef14
Salima Amlani, R Andrew McIvor. (2011) Montelukast in childhood asthma: what is the evidence for its use?. Expert Review of Respiratory Medicine 5:1, 17-25
CrossRef15
Alexandra Ahmet, Harold Kim, Sheldon Spier. (2011) Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy, Asthma & Clinical Immunology 7:1, 13
CrossRef16
Peter Small, Harold Kim. (2011) Allergic rhinitis. Allergy, Asthma & Clinical Immunology 7:Suppl 1, S3
CrossRef17
Soren Erik Pedersen, Suzanne S. Hurd, Robert F. Lemanske, Allan Becker, Heather J. Zar, Peter D. Sly, Manuel Soto-Quiroz, Gary Wong, Eric D. Bateman. (2011) Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatric Pulmonology 46:1, 1-17
CrossRef18
Kevin R. Murphy. (2010) Adherence to inhaled corticosteroids: Comparison of available therapies. Pulmonary Pharmacology & Therapeutics 23:5, 384-388
CrossRef19
Israel Amirav, Michael Newhouse. (2010) Reply. Journal of Allergy and Clinical Immunology 126:3, 676-677
CrossRef20
Paulo A.M. Camargos, Laura M.L.B.F. Lasmar. (2010) Effects of beclomethasone and factors related to asthma on the growth of prepubertal children. Respiratory Medicine 104:7, 951-956
CrossRef21
Steve Turner, Mike Thomas, Stephen C. Lazarus, Moshe Zutler, Lori Connors, Paul K. Keith, Paul L. P. Brand. (2010) Commentaries on ‘Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children’. Evidence-Based Child Health: A Cochrane Review Journal 5:2, 959-966
CrossRef22
Anke Lüührmann, Thomas Tschernig, Heiko von der Leyen, Markus Hecker, Reinhard Pabst, Andreas H. Wagner. (2010) Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model. Experimental Lung Research 36:2, 85-93
CrossRef23
MARKKU TURPEINEN, HANNA RAITIO, ANNA S. PELKONEN, KURT NIKANDER, RITVA SORVA, OLOF SELROOS, KAISU JUNTUNEN-BACKMAN, TARI HAAHTELA. (2010) Skin Thickness in Children Treated With Daily or Periodical Inhaled Budesonide for Mild Persistent Asthma. The Helsinki Early Intervention Childhood Asthma Study. Pediatric Research 67:2, 221-225
CrossRef24
Sankei Nishima, Akihiro Morikawa, Toshishige Inoue. (2010) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology 24:5, 725-740
CrossRef25
Paul C Potter. (2010) Current guidelines for the management of asthma in young children. Allergy, Asthma and Immunology Research 2:1, 1
CrossRef26
Sankei Nishima, Akihiro Morikawa, Toshishige Inoue. (2010) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology 24:3, 321-336
CrossRef27
Bart L. Rottier, Eric J. Duiverman. (2009) Anti-inflammatory drug therapy in asthma. Paediatric Respiratory Reviews 10:4, 214-219
CrossRef28
Eliza L.Y. Wong, Rita Yn Tz Sung, Ting Fan Leung, Yeuk Oi Wong, Albert M.C. Li, Kam Lau Cheung, Chun Kwok Wong, Tai Fai Fok, Ping Chung Leung. (2009) Randomized, Double-Blind, Placebo-Controlled Trial of Herbal Therapy for Children with Asthma. The Journal of Alternative and Complementary Medicine 15:10, 1091-1097
CrossRef29
Louis-Philippe Boulet, Hélène Turcotte, Philippe Prince, Catherine Lemière, Ronald Olivenstein, Catherine Laprise, Pierre Larivée, Paul Bégin, Michel Laviolette. (2009) Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Respiratory Medicine 103:10, 1554-1563
CrossRef30
David Weldon. (2009) The effects of corticosteroids on bone growth and bone density. Annals of Allergy, Asthma & Immunology 103:1, 3-11
CrossRef31
Barbara Watts. (2009) Outpatient management of asthma in children age 5-11 years: Guidelines for practice. Journal of the American Academy of Nurse Practitioners 21:5, 261-269
CrossRef32
Fanta, Christopher H., . (2009) Asthma. New England Journal of Medicine 360:10, 1002-1014
Full Text33
Paul D. Robinson, Peter Van Asperen. (2009) Asthma in Childhood. Pediatric Clinics of North America 56:1, 191-226
CrossRef34
Jian Xu, Sreedharan Nair Sabarinath, Hartmut Derendorf. (2009) Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children. European Journal of Pharmaceutical Sciences 36:1, 110-121
CrossRef35
Nancy Sarver, Kevin Murphy. (2009) Management of asthma: New approaches to establishing control. Journal of the American Academy of Nurse Practitioners 21:1, 54-65
CrossRef36
Andrew Bush. (2009) Role of corticosteroids in preschool wheeze: going, going, but not gone. Therapy 6:1, 31-39
CrossRef37
Peter J. Barnes. 2009. Corticosteroids. , 639-653.
CrossRef38
Christina Lee, Jonathan Corren. (2008) Budesonide/formoterol in the treatment of asthma. Expert Review of Respiratory Medicine 2:5, 551-564
CrossRef39
David P. Skoner, Deborah A. Gentile, William J. Doyle. (2008) Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. Annals of Allergy, Asthma & Immunology 101:4, 431-436
CrossRef40
Horng-Sheng Shiue, Yun-Shien Lee, Chi-Neu Tsai, Yu-Mei Hsueh, Joen-Rong Sheu, Hen-Hong Chang. (2008) DNA Microarray Analysis of the Effect on Inflammation in Patients Treated with Acupuncture for Allergic Rhinitis. The Journal of Alternative and Complementary Medicine 14:6, 689-698
CrossRef41
K. H. Carlsen, S. D. Anderson, L. Bjermer, S. Bonini, V. Brusasco, W. Canonica, J. Cummiskey, L. Delgado, S. R. Del Giacco, F. Drobnic, T. Haahtela, K. Larsson, P. Palange, T. Popov, P. van Cauwenberge. (2008) Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA 2 LEN. Allergy 63:5, 492-505
CrossRef42
Kai-Håkon Carlsen, Karin CL Carlsen. (2008) Pharmaceutical treatment strategies for childhood asthma. Current Opinion in Allergy and Clinical Immunology 8:2, 168-176
CrossRef43
R. Iles, R. W. Williams, A. Deeb, R. Ross-Russell, C.L. Acerini. (2008) A longitudinal assessment of the effect of inhaled fluticasone propionate therapy on adrenal function and growth in young children with asthma. Pediatric Pulmonology 43:4, 354-359
CrossRef44
Lora J. Stewart. (2008) Pediatric Asthma. Primary Care: Clinics in Office Practice 35:1, 25-40
CrossRef45
Sankei Nishima, Tokuko Mukouyama, Akira Akasawa, Motohiro Ebisawa, Kazuhiro Kimura, Komei Ito, Naomi Kondo, Takao Fujisawa, Isao Tanaka, Masanori Ikeda, Nobuyuki Kodani, Hiroshi Odajima, Haruki Mikawa. (2008) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunollogy 22:1, 116-128
CrossRef46
Camilla Christensson, Anders Thorén, Bengt Lindberg. (2008) Safety of Inhaled Budesonide. Drug Safety 31:11, 965-988
CrossRef47
Toshishige Inoue. (2008) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunollogy 22:2, 207-216
CrossRef48
Elaine Lau. (2007) Pediatric considerations in asthma*. Canadian Pharmacists Journal 140:sp3, s31-s32
CrossRef49
Søren Pedersen, Lone Agertoft, Debora Williams-Herman, Olga Kuznetsova, Theodore F. Reiss, Barbara Knorr, S. Balachandra Dass, Ole D. Wolthers. (2007) Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatric Pulmonology 42:9, 838-843
CrossRef50
Andrea von Berg, Renate Engelstätter, Predrag Minic, Miodrag Sréckovic, Maria Luz Garcia Garcia, Tadeusz Latoś, Jan H. Vermeulen, Stefan Leichtl, Stefan Hellbardt, Thomas D. Bethke. (2007) Comparison of the efficacy and safety of ciclesonide 160
?g once daily vs. budesonide 400
CrossRef51
&NA;. (2007) Inhaled corticosteroids appear to have little risk of causing adverse effects on growth, bone density or cortisol levels in children with asthma. Drugs & Therapy Perspectives 23:7, 21-23
CrossRef52
Joseph D Spahn, Stanley J Szefler. (2007) Steroid therapy for asthma in children. Current Opinion in Pediatrics 19:3, 300-305
CrossRef53
Eli O. Meltzer, Carlos E. Baena-Cagnani, Paul Chervinsky, George E. Stewart II, Edwin A. Bronsky, Barry N. Lutsky. (2007) Once-Daily Mometasone Furoate Administered by Dry Powder Inhaler for the Treatment of Children with Persistent Asthma. Pediatric Asthma, Allergy & Immunology 20:2, 67-82
CrossRef54
Arnon Elizur, Noam Pollack, Sarah E. Boslaugh, Yakar Kannai, Yitzhak Katz. (2007) Maternal positive skin prick test results and asthma prediction after early childhood wheezing. Annals of Allergy, Asthma & Immunology 98:6, 540-545
CrossRef55
Michael B. Anthracopoulos, Anastasios Papadimitriou, Demosthenes B. Panagiotakos, Garyfalia Syridou, Eleni Giannakopoulou, Andrew Fretzayas, Polyxeni Nicolaidou, Kostas N. Priftis. (2007) Growth deceleration of children on inhaled corticosteroids is compensated for after the first 12 months of treatment. Pediatric Pulmonology 42:5, 465-470
CrossRef56
Bradley E. Chipps, Stanley J. Szefler, F. Estelle R. Simons, Tmirah Haselkorn, David R. Mink, Yamo Deniz, June H. Lee. (2007) Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. Journal of Allergy and Clinical Immunology 119:5, 1156-1163
CrossRef57
Carlos E Baena-Cagnani, Giovanni Passalacqua, Maximiliano Gómez, Mario E Zernotti, G Walter Canonica. (2007) New perspectives in the treatment of allergic rhinitis and asthma in children. Current Opinion in Allergy and Clinical Immunology 7:2, 201-206
CrossRef58
Giovanni A. Rossi, Franklin Cerasoli, Mario Cazzola. (2007) Safety of inhaled corticosteroids: Room for improvement. Pulmonary Pharmacology & Therapeutics 20:1, 23-35
CrossRef59
Hideko Watanabe, Seiichi Yano, Akihiko Kageyama. (2007) Pharmacological and clinical profile of Budesonide inhalation suspension (Pulmicort¨ inhalation liquid), an inhaled steroid drug for asthma. Folia Pharmacologica Japonica 129:3, 197-207
CrossRef60
Tanya Gulliver, Ronald Morton, Nemr Eid. (2007) Inhaled Corticosteroids in Children with Asthma. Pediatric Drugs 9:3, 185-194
CrossRef61
Erika Von Mutius, Thomas Nicolai. 2007. Allergien. , 707-735.
CrossRef62
Paul L McCormack, Katherine A Lyseng-Williamson. (2007) Budesonide/Formoterol. Drugs 67:16, 2407-2431
CrossRef63
Christine A. Sorkness, Robert F. Lemanske, David T. Mauger, Susan J. Boehmer, Vernon M. Chinchilli, Fernando D. Martinez, Robert C. Strunk, Stanley J. Szefler, Robert S. Zeiger, Leonard B. Bacharier, Gordon R. Bloomberg, Ronina A. Covar, Theresa W. Guilbert, Gregory Heldt, Gary Larsen, Michael H. Mellon, Wayne J. Morgan, Mark H. Moss, Joseph D. Spahn, Lynn M. Taussig. (2007) Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. Journal of Allergy and Clinical Immunology 119:1, 64-72
CrossRef64
Małgorzata Olszowiec-Chlebna, Iwona Stelmach. (2007) Czynniki ryzyka wystąpienia ogólnoustrojowych działań niepożądanych podczas stosowania glikokortykosteroidów wziewnych u dzieci chorych na astmę oskrzelową. Pediatria Polska 82:1, 49-55
CrossRef65
Alexander C. Ferguson, Hugo P. Van Bever, Alejandro M. Teper, Olga Lasytsya, Caroline H. Goldfrad, Philip J. Whitehead. (2007) A comparison of the relative growth velocities with budesonide and fluticasone propionate in children with asthma. Respiratory Medicine 101:1, 118-129
CrossRef66
Wan C. TAN, Carl J. LAMM, Yu-Zhi CHEN, Paul M. O'BYRNE, Søren PEDERSEN, William W. BUSSE, Stefan V. OHLSSON, Anders ULLMAN, Bertil ANDERSSON, Romain A. PAUWELS. (2006) Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-year results of the START study. Respirology 11:6, 767-775
CrossRef67
Paul M O'Byrne, Krishnan Parameswaran. (2006) Pharmacological management of mild or moderate persistent asthma. The Lancet 368:9537, 794-803
CrossRef68
Ronald Dahl. (2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respiratory Medicine 100:8, 1307-1317
CrossRef69
M. Merino Hernández, J. Aranguren Castro, M. Callén Blecua, J. Elorz Lambarri, A. Etxeberria Agirre, J.B. Galdiz Iturri, I. Irízar Aranburu, I. Lekue Alkorta, M.A. Lizarraga Azparren, M. Maeztu López de Alda, M.ªL. Marqués González, A. Martínez González, M. Merino Hernández, J.M. Merino Nazábal, R. Rotaeche del Campo, M. Villar Álvarez. (2006) Guía de práctica clínica sobre asma (2.ª parte). Anales de Pediatría 65:1, 51-66
CrossRef70
Allan B. Becker, Olga Kuznetsova, J Vermeulen, Manuel E. Soto-Quiros, Betty Young, Theodore F. Reiss, S. Balachandra Dass, Barbara A. Knorr. (2006) Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Annals of Allergy, Asthma & Immunology 96:6, 800-807
CrossRef71
Staffan Edsbacker, Carl-Johan Johansson. (2006) Airway Selectivity: An Update of Pharmacokinetic Factors Affecting Local and Systemic Disposition of Inhaled Steroids. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:6, 523-536
CrossRef72
Guilbert, Theresa W., Morgan, Wayne J., Zeiger, Robert S., Mauger, David T., Boehmer, Susan J., Szefler, Stanley J., Bacharier, Leonard B., Lemanske, Robert F. Jr., Strunk, Robert C., Allen, David B., Bloomberg, Gordon R., Heldt, Gregory, Krawiec, Marzena, Larsen, Gary, Liu, Andrew H., Chinchilli, Vernon M., Sorkness, Christine A., Taussig, Lynn M., Martinez, Fernando D., . (2006) Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma. New England Journal of Medicine 354:19, 1985-1997
Full Text73
T. W. Vries, J. J. Langen-Wouterse, E. Puijenbroek, E. J. Duiverman, L. T. W. Jong-Van den Berg. (2006) Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. European Journal of Clinical Pharmacology 62:5, 343-346
CrossRef74
Roberto J. Rona, Nigel C. Smeeton, Claudio Vargas, Patricia Bustos, Hugo Amigo. (2006) Untreated asthma, final height and sitting height/leg length ratio in Chile. Respiratory Medicine 100:5, 911-917
CrossRef75
Kevin Murphy, Tom Uryniak, Brandon Simpson, Liza O'Dowd. (2006) Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Annals of Allergy, Asthma & Immunology 96:5, 723-730
CrossRef76
Leonard Bielory, Michael Blaiss, Stanley M. Fineman, Dennis K. Ledford, Phil Lieberman, F. Estelle R. Simons, David P. Skoner, William W. Storms. (2006) Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology 96:4, 514-525
CrossRef77
P. M. Gustafsson, L. Watson, K. J. Davis, K. F. Rabe. (2006) Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. International Journal of Clinical Practice 60:3, 321-334
CrossRef78
Kostas N. Priftis, Anastasios Papadimitriou, Michael B. Anthracopoulos, Evi Gatsopoulou, Andrew Fretzayas, Polyxeni Nicolaidou, George P. Chrousos. (2006) Adrenal Function Improves in Asthmatic Children on Inhaled Steroids: A Longitudinal Study. Neuroimmunomodulation 13:1, 56-62
CrossRef79
M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc. (2006) Use of the Low-Dose Corticotropin Stimulation Test for the Monitoring of Children with Asthma Treated with Inhaled Corticosteroids. Hormone Research 66:2, 51-60
CrossRef80
Kwan Hyoung Kim. (2006) Pharmacology in Airway Diseases. Tuberculosis and Respiratory Diseases 60:1, 21
CrossRef81
S??ren Pedersen. (2006) Clinical Safety of Inhaled Corticosteroids for Asthma in Children. Drug Safety 29:7, 599-612
CrossRef82
Niels Mygind, Valerie Lund. (2006) Intranasal Corticosteroids for Nasal Polyposis. Treatments in Respiratory Medicine 5:2, 93-102
CrossRef83
2006. Corticosteroids—glucocorticoids, inhaled. , 958-977.
CrossRef84
Sankei Nishima, Akihiro Morikawa, Toshiyuki Nishimuta. (2006) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunollogy 20:3, 218-230
CrossRef85
C. F. Poets. (2005) Prävention und Therapie der bronchopulmonalen Dysplasie. Monatsschrift Kinderheilkunde 153:12, 1140-1147
CrossRef86
Joseph Spahn, Anne-Marie Irani. (2005) Regular Use of Inhaled Corticosteroids in Children with Persistent Asthma. Pediatric Asthma, Allergy & Immunology 18:4, 247-258
CrossRef87
Tanya Gulliver, Nemr Eid. (2005) Effects of Glucocorticoids on the Hypothalamic-Pituitary-Adrenal Axis in Children and Adults. Immunology and Allergy Clinics of North America 25:3, 541-555
CrossRef88
Lars Thorsson, David Geller. (2005) Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Respiratory Medicine 99:7, 836-849
CrossRef89
Eli Gazala, Renata Sadka, Natalya Bilenko. (2005) Parents' Fears and Concerns Toward Inhaled Corticosteroid Treatment for Their Asthmatic Children. Pediatric Asthma, Allergy & Immunology 18:2, 82-87
CrossRef90
Terence Stephenson. (2005) How children's responses to drugs differ from adults. British Journal of Clinical Pharmacology 59:6, 670-673
CrossRef91
Anne-Marie Irani. (2005) The challenge of mild persistent asthma. Annals of Allergy, Asthma & Immunology 94:5, 517-527
CrossRef92
Jeffrey G. Leflein, James W. Baker, Howard Eigen, Ewa Lyzell, Lawrence McDermott. (2005) Safety features of budesonide inhalation suspension in the long-term treatment of asthma in young children. Advances in Therapy 22:3, 198-207
CrossRef93
L Joseph Melton, Ashok Patel, Sara J Achenbach, Ann L Oberg, John W Yunginger. (2005) Long-Term Fracture Risk Among Children With Asthma: A Population-Based Study. Journal of Bone and Mineral Research 20:4, 564-570
CrossRef94
Albert L. Sheffer, Mike Silverman, Ann J. Woolcock, Patricia V. Díaz, Bengt Lindberg, Bertil Lindmark. (2005) Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Annals of Allergy, Asthma & Immunology 94:1, 48-54
CrossRef95
Edward J. O'Connell. (2005) Optimizing inhaled corticosteroid therapy in children with chronic asthma. Pediatric Pulmonology 39:1, 74-83
CrossRef96
William E Berger. (2005) Budesonide Inhalation Suspension for the Treatment of Asthma in Infants and Children. Drugs 65:14, 1973-1989
CrossRef97
Kevin J. Mortimer, T.W. Harrison, A.E. Tattersfield. (2005) Effects of inhaled corticosteroids on bone. Annals of Allergy, Asthma & Immunology 94:1, 15-22
CrossRef98
D. Ufuk Altintas, G. Bingol Karakoc, S. Can, M. Yilmaz, S. Guneser Kendirli. (2005) The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children. Allergologia et Immunopathologia 33:4, 204-209
CrossRef99
Vagn Braendholt Jensen, Inger Merete Jorgensen, Kirsten Braendholt Rasmussen, Christian Molgaard, Palle Prahl. (2004) Bone mineral status in children with cow milk allergy. Pediatric Allergy and Immunology 15:6, 562-565
CrossRef100
Monali J Bhosle, Rahul A Shenolikar, Amit S Kulkarni, Rajesh Balkrishnan. (2004) Outcomes associated with inhaled corticosteroid use in asthma and COPD: an update. Expert Review of Pharmacoeconomics & Outcomes Research 4:6, 645-656
CrossRef101
O. D. Wolthers, C. Heuck. (2004) Assessment of the relation between short and intermediate term growth in children with asthma treated with inhaled glucocorticoids. Allergy 59:11, 1193-1197
CrossRef102
Peter T. Daley-Yates, David H. Richards. (2004) Relationship between systemic corticosteroid exposureand growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clinical Therapeutics 26:11, 1905-1919
CrossRef103
Kevin R. Murphy, Beth Cecil, Nancy L. Sarver. (2004) Asthma: Helping Patients Breathe Easier. The Nurse Practitioner 29:10, 38-55
CrossRef104
Sham Kukreja, S. Sanjay, Gautam Ghosh, K. K. Aggarwal, Ashok Moharana. (2004) Montelukast — evaluation in 6 to 14 years old children with persistent asthma — pediatric montelukast study group. The Indian Journal of Pediatrics 71:9, 811-815
CrossRef105
Stanley J. Szefler, Ewa Lyzell, Sherahe Fitzpatrick, Mario Cruz-Rivera. (2004) Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Annals of Allergy, Asthma & Immunology 93:1, 83-90
CrossRef106
William E. Berger, Gail G. Shapiro. (2004) The use of inhaled corticosteroids for persistent asthma in infants and young children. Annals of Allergy, Asthma & Immunology 92:4, 387-400
CrossRef107
Kai-Håkon Carlsen. (2004) Therapeutic strategies for allergic airways diseases. Paediatric Respiratory Reviews 5:1, 45-51
CrossRef108
T. Vanto, K.M. Hämäläinen, M. Vahteristo, S. Wille, F. Njå, N. Hyldebrandt. (2004) Comparison of Two Budesonide Dry Powder Inhalers in the Treatment of Asthma in Children. Journal of Aerosol Medicine 17:1, 15-24
CrossRef109
Amanda L. Griffiths, Derrick Sim, Boyd Strauss, Christine Rodda, David Armstrong, Nicholas Freezer. (2004) Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatric Pulmonology 37:2, 116-121
CrossRef110
Staffan Edsb??cker, Tommy Andersson. (2004) Pharmacokinetics of Budesonide (Entocort??? EC) Capsules for Crohn???s Disease. Clinical Pharmacokinetics 43:12, 803-821
CrossRef111
Richard Hubbard, Anne Tattersfield. (2004) Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People. Drugs & Aging 21:10, 631-638
CrossRef112
Robert Heinle, Annie Linton, Aaron S. Chidekel. (2003) Exercise-induced Vocal Cord Dysfunction Presenting as Asthma in Pediatric Patients: Toxicity of Inappropriate Inhaled Corticosteroids and the Role of Exercise Laryngoscopy. Pediatric Asthma, Allergy & Immunology 16:4, 215-224
CrossRef113
Richard J. Scarfone, Eron Friedlaender. (2003) Corticosteroids in Acute Asthma: Past, Present, and Future. Pediatric Emergency Care 19:5, 355-361
CrossRef114
Sushil Kabra, Rakesh Lodha. 2003. Bronchial Asthma. , 209-229.
CrossRef115
David B. Allen, Leonard Bielory, Hartmut Derendorf, Robert Dluhy, Gene L. Colice, Stanley J. Szefler. (2003) Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology 112:3, S1-S40
CrossRef116
Roland Buhl. (2003) Budesonide/formoterol for the treatment of asthma. Expert Opinion on Pharmacotherapy 4:8, 1393-1406
CrossRef117
Stanley Szefler, S
CrossRef118
Sabina A Antoniu. (2003) The START study: when to start to treat with inhaled steroids in asthma?. Expert Review of Pharmacoeconomics & Outcomes Research 3:3, 223-225
CrossRef119
C. Moller, H. Ahlstrom, K.-A. Henricson, L.-A. Malmqvist, A. Akerlund, H. Hildebrand. (2003) Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:6, 816-822
CrossRef120
Mark E. Mehle. (2003) Are nasal steroids safe?. Current Opinion in Otolaryngology & Head and Neck Surgery 11:3, 201-205
CrossRef121
R COVAR, J SPAHN. (2003) Treating the wheezing infant. Pediatric Clinics of North America 50:3, 631-654
CrossRef122
J K. Aronson. (2003) Features of this month's Journal. British Journal of Clinical Pharmacology 55:4, 327-328
CrossRef123
Ian J. Smith, Mark Parry-Billings. (2003) The inhalers of the future? A review of dry powder devices on the market today. Pulmonary Pharmacology & Therapeutics 16:2, 79-95
CrossRef124
Romain A Pauwels, Søren Pedersen, William W Busse, Wan C Tan, Yu-Zhi Chen, Stefan V Ohlsson, Anders Ullman, Carl Johan Lamm, Paul M O'Byrne. (2003) Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. The Lancet 361:9363, 1071-1076
CrossRef125
E HUOVINEN, J KAPRIO, M KOSKENVUO. (2003) Factors associated to lifestyle and risk of adult onset asthma. Respiratory Medicine 97:3, 273-280
CrossRef126
T. J. Steenhuis, W. M. C. Aalderen, M. O. Hoekstra. (2003) Allergie op de kinderleeftijd – een rol voor primaire preventie. Tijdschrift voor kindergeneeskunde 71:6, 1-6
CrossRef127
John J. Murray, Csaba Rusznak. (2003) Asthma and rhinosinusitis. Current Opinion in Otolaryngology & Head and Neck Surgery 11:1, 49-53
CrossRef128
David Coghlan, Colin Powell. (2003) Treatment of Childhood Asthma. Pediatric Drugs 5:10, 685-698
CrossRef129
Tabitha L Randell, Kim C Donaghue, Geoffrey R Ambler, Christopher T Cowell, Dominic A Fitzgerald, Peter P Van Asperen. (2003) Safety of the Newer Inhaled Corticosteroids in Childhood Asthma. Pediatric Drugs 5:7, 481-504
CrossRef130
James E. Kemp. (2003) Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma. Clinical Therapeutics 25, C15-C27
CrossRef131
S. K. Kabra, Rakesh Lodha. (2003) Long-term management of asthma. The Indian Journal of Pediatrics 70:1, 63-72
CrossRef132
Alessandro Salvatoni, Elena Piantanida, Luana Nosetti, Luigi Nespoli. (2003) Inhaled Corticosteroids in Childhood Asthma. Pediatric Drugs 5:6, 351-361
CrossRef133
Edward J. O'Connell. (2003) Review of the unique properties of budesonide. Clinical Therapeutics 25, C42-C60
CrossRef134
David P. Skoner, Deborah Gentile, Betty Angelini, Robert Kane, Deborah Birdsall, Donald Banerji. (2003) The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Annals of Allergy, Asthma & Immunology 90:1, 56-62
CrossRef135
David S. Pearlman. (2003) Preclinical properties of budesonide: Translation to the clinical setting. Clinical Therapeutics 25, C75-C91
CrossRef136
Johanna C. Escher, Jan A. J. M. Taminiau, Edward E. S. Nieuwenhuis, Hans A. B??ller, Richard J. Grand. (2003) Treatment of Inflammatory Bowel Disease in Childhood: Best Available Evidence. Inflammatory Bowel Diseases 9:1, 34-58
CrossRef137
Hanns Kaiser. (2003) Cortisontherapie heute. Wiener Klinische Wochenschrift 115:1-2, 6-21
CrossRef138
Kenneth R. Chapman. (2003) The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clinical Therapeutics 25, C2-C14
CrossRef139
David E. Skoner. (2003) Therapeutic margin of budesonide in patients with mild to severe asthma. Clinical Therapeutics 25, C61-C74
CrossRef140
R.M. Angus. (2002) Inhaled Corticosteroids (Budesonide): the Cornerstone of Asthma Therapy – What are the Options?. Pulmonary Pharmacology & Therapeutics 15:6, 479-484
CrossRef141
J. Kips. (2002) Managing a Variable Disease. Pulmonary Pharmacology & Therapeutics 15:6, 485-490
CrossRef142
Shmuel Goldberg, Tsurit Einot, Nurit Algur, Shimshon Schwartz, Alan C. Greenberg, Elie Picard, Dov Virgilis, Eitan Kerem. (2002) Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer. Annals of Allergy, Asthma & Immunology 89:6, 566-571
CrossRef143
Lars Larsson, Maria Gerhardsson de Verdier, Bertil Lindmark, Ensio Norjavaara. (2002) Budesonide-treated asthmatic adolescents attain target height: a population-based follow-up study from Sweden. Pharmacoepidemiology and Drug Safety 11:8, 715-720
CrossRef144
Jason Krahnke, David Skoner. (2002) Benefit and risk management for steroid treatment in upper airway diseases. Current Allergy and Asthma Reports 2:6, 507-512
CrossRef145
A. Tal, G. Simon, J.H. Vermeulen, V. Petru, N. Cobos, M.L. Everard, K. de Boeck. (2002) Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 34:5, 342-350
CrossRef146
Wolthers, Ole D., , Allen, David B., . (2002) Inhaled Corticosteroids, Growth, and Compliance. New England Journal of Medicine 347:15, 1210-1211
Full Text147
A. W. A. Kamps, P. L. P. Brand, J. M. ten Berg-Vinke, R. J. Roorda. (2002) Kennis over werking en mogelijke bijwerkingen van inhalatiemedicatie vaak onvoldoende bij ouders van kinderen met astma. Tijdschrift voor kindergeneeskunde 70:2, 213-216
CrossRef148
S. Pedersen. (2002) Long-term outcomes in paediatric asthma. Allergy 57:s74, 58-74
CrossRef149
Y. S. NOUT, K. W. HINCHCLIFF, V. F. SAMII, C. W. KOHN, E. JOSE-CUNILLERAS, S. M. REED. (2002) Chronic pulmonary disease with radiographic interstitial opacity (interstitial pneumonia) in foals. Equine Veterinary Journal 34:6, 542-548
CrossRef150
Wytske J. Fokkens, Endre Cserháti, José Manuel Lopes Santos, Fatima Praca, Marinus van Zanten, Alexander Schade, György Simon. (2002) Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Annals of Allergy, Asthma & Immunology 89:3, 279-284
CrossRef151
Kian Fan Chung. (2002) Current and potential improvements in the treatment of asthma from increased understanding of airway pathophysiology. Allergology International 51:3, 153-166
CrossRef152
Vibeke Backer, Steen Nepper-Christensen, Charlotte Suppli Ulrik, Marie-Louise von Linstow, Celeste Porsbjerg. (2002) Factors associated with asthma in young Danish adults. Annals of Allergy, Asthma & Immunology 89:2, 148-154
CrossRef153
SENJA KANNISTO, MATTI KORPPI, PEKKA ARIKOSKI, KYLLIKKI REMES, AND, RAIMO VOUTILAINEN. (2002) Biochemical Markers of Bone Metabolism in Relation to Adrenocortical and Growth Suppression During the Initiation Phase of Inhaled Steroid Therapy. Pediatric Research 52:2, 258-262
CrossRef154
Howard Eigen. (2002) Efficacy of budesonide in inhaled corticosteroid—naive patients and patients with mild persistent asthma. Clinical Therapeutics 24:7, 1035-1048
CrossRef155
Staffan Edsbäcker, Ralph Brattsand. (2002) Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Annals of Allergy, Asthma & Immunology 88:6, 609-616
CrossRef156
Lee M. Sanders, Judith R. McCullough. (2002) Helping Families Improve Self-Management of Pediatric Asthma: A Guide for the Primary Care Physician. Pediatric Case Reviews 2:2, 112-125
CrossRef157
H. William Kelly, Hengameh Heidarian- Raissy. (2002) The use of inhaled corticosteroids in children with asthma. Current Allergy and Asthma Reports 2:2, 133-143
CrossRef158
David B. Allen. (2002) Safety of inhaled corticosteroids in children. Pediatric Pulmonology 33:3, 208-220
CrossRef159
David Skoner. (2002) Update of growth effects of inhaled and intranasal corticosteroids. Current Opinion in Allergy and Clinical Immunology 2:1, 7-10
CrossRef160
P.J. Barnes. (2002) The role of inflammation and anti-inflammatory medication in asthma. Respiratory Medicine 96, S9-S15
CrossRef161
A. Tal. (2002) Symbicort®: controlling asthma in children. Respiratory Medicine 96, S23-S28
CrossRef162
David P. Skoner. (2002) Growth effects of asthma and asthma therapy. Current Opinion in Pulmonary Medicine 8:1, 45-49
CrossRef163
Conroy A. Wong, Ganesamoorthy Subakumar, Paul M. Casey. (2002) Effects of asthma and asthma therapies on bone mineral density. Current Opinion in Pulmonary Medicine 8:1, 39-44
CrossRef164
Alia Bazzy-Asaad. (2001) Safety of inhaled corticosteroids in children with asthma. Current Opinion in Pediatrics 13:6, 523-527
CrossRef165
Stuart E. Turvey. (2001) Atopic diseases of childhood. Current Opinion in Pediatrics 13:5, 487-495
CrossRef166
Ensio Norjavaara, Maria Gerhardsson de Verdier, Bertil Lindmark. (2001) Adult height in women with childhood asthma - a population-based study. Pharmacoepidemiology and Drug Safety 10:2, 121-125
CrossRef167
Katherine H. Creese, Iolo J. M. Doull. (2001) Effects of inhaled corticosteroids on growth in asthmatic children. Current Allergy and Asthma Reports 1:2, 122-126
CrossRef168
F. Estelle R. Simons. (2001) The Benefits of Long-Term Inhaled Glucocorticosteroid Treatment in Children with Asthma Outweigh the Risks. Pediatric Research 49:3, 315-316
CrossRef169
(2001) Asthma, Corticosteroids, and Growth. New England Journal of Medicine 344:8, 607-608
Full Text170
Stanley P. Galant, Robert Wilkinson. (2001) Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child. BioDrugs 15:7, 453-463
CrossRef171
Karen M. Hvizdos, Blair Jarvis. (2000) Budesonide Inhalation Suspension. Drugs 60:5, 1141-1178
CrossRef172
Wohl, Mary Ellen B., Majzoub, Joseph A., . (2000) Asthma, Steroids, and Growth. New England Journal of Medicine 343:15, 1113-1114
Full Text173
&NA;. (2000) Inhaled budesonide in children: no long-term impact on growth?. Inpharma Weekly &NA;:1260, 19
CrossRef174
&NA;. (2000) Inhaled budesonide in children has no long-term impact on growth. Reactions Weekly &NA;:824, 4
CrossRef
